OAM
GRCE

Oxford Asset Management’s Grace Therapeutics GRCE Stock Holding History

Oxford Asset Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,747
Closed -$676K – 1365
2019
Q4 		$676K Buy
+5,747
New +$568K 0.02% 1077

Other funds holding GRCE

Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JLBC
J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Oxford Asset Management's GRCE Position: Q1 2020 in Review

Oxford Asset Management sold out of Grace Therapeutics (GRCE) in Q1 2020, closing a stake of 5,747 shares — an estimated $676K sold.

Oxford Asset Management first reported a position in GRCE in Q4 2019 and held it in 1 quarter. The position peaked at $676K in Q4 2019. 26 funds tracked by Wall St. Rank hold GRCE as of Q1 2020.

  • Oxford Asset Management reported no remaining Grace Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 5,747 Grace Therapeutics shares in Q1 2020, an estimated $676K.
  • Oxford Asset Management first reported a position in Grace Therapeutics in Q4 2019 and held it in 1 quarter.
  • Oxford Asset Management's Grace Therapeutics position peaked at $676K in Q4 2019.
  • 26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.